The Food and Drug Administration on March 10 approved a long-available generic drug called leucovorin for use against a rare disorder that causes autism-like symptoms.
Regulators approved the drug for treating cerebral folate deficiency in children and adults who have a confirmed variant in the folate receptor 1 gene (FOLR1), based on a systemic review of studies, rather than clinical trial data.
